356 related articles for article (PubMed ID: 33964370)
1. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
Hyun J; Al Abo M; Dutta RK; Oh SH; Xiang K; Zhou X; Maeso-Díaz R; Caffrey R; Sanyal AJ; Freedman JA; Patierno SR; Moylan CA; Abdelmalek MF; Diehl AM
J Hepatol; 2021 Sep; 75(3):623-633. PubMed ID: 33964370
[TBL] [Abstract][Full Text] [Related]
2. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
3. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.
White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C
Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.
Mooring M; Fowl BH; Lum SZC; Liu Y; Yao K; Softic S; Kirchner R; Bernstein A; Singhi AD; Jay DG; Kahn CR; Camargo FD; Yimlamai D
Hepatology; 2020 May; 71(5):1813-1830. PubMed ID: 31505040
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis.
Wang Y; Zhu Y; Gu Y; Ma M; Wang Y; Qi S; Zeng Y; Zhu R; Wang X; Yu P; Xu J; Shu Y; Yu FX
Cell Rep; 2021 Aug; 36(8):109596. PubMed ID: 34433060
[TBL] [Abstract][Full Text] [Related]
6. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators.
Lavado A; He Y; Paré J; Neale G; Olson EN; Giovannini M; Cao X
Development; 2013 Aug; 140(16):3323-34. PubMed ID: 23863479
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
[TBL] [Abstract][Full Text] [Related]
9. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
[TBL] [Abstract][Full Text] [Related]
10. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
11. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase.
Salloum S; Jeyarajan AJ; Kruger AJ; Holmes JA; Shao T; Sojoodi M; Kim MH; Zhuo Z; Shroff SG; Kassa A; Corey KE; Khan SK; Lin W; Alatrakchi N; Schaefer EAK; Chung RT
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1297-1310. PubMed ID: 34118488
[TBL] [Abstract][Full Text] [Related]
12. Two Hippo signaling modules orchestrate liver size and tumorigenesis.
Qi S; Zhong Z; Zhu Y; Wang Y; Ma M; Wang Y; Liu X; Jin R; Jiao Z; Zhu R; Sha Z; Dang K; Liu Y; Lim DS; Mao J; Zhang L; Yu FX
EMBO J; 2023 Jun; 42(11):e112126. PubMed ID: 36919851
[TBL] [Abstract][Full Text] [Related]
13. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
[TBL] [Abstract][Full Text] [Related]
14. Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression.
Shi Y; Bollam SR; White SM; Laughlin SZ; Graham GT; Wadhwa M; Chen H; Nguyen C; Vitte J; Giovannini M; Toretsky J; Yi C
Dev Cell; 2016 Nov; 39(4):452-465. PubMed ID: 27818180
[TBL] [Abstract][Full Text] [Related]
15. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
16. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
17. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
[TBL] [Abstract][Full Text] [Related]
18. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.
Moon H; Park H; Chae MJ; Choi HJ; Kim DY; Ro SW
BMC Cancer; 2022 Apr; 22(1):423. PubMed ID: 35439973
[TBL] [Abstract][Full Text] [Related]
19. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Autelli R; Novo E; Bocca C; Villano G; Ramavath NN; Younes R; Tusa I; Rovida E; Pontisso P; Bugianesi E; Albano E; Parola M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):459-482. PubMed ID: 34655812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
